started · updated
ASN Kidney Week 2026 highlights new therapies and digital tools for CKD
At the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, researchers presented significant advancements in the management of chronic kidney disease (CKD). Clinical trial data for finerenone showed it slowed eGFR decline in patients with non-diabetic CKD, even when used alongside SGLT2 inhibitors. Additionally, a phase 2 trial of balcinrenone combined with dapagliflozin demonstrated a reduction in systolic blood pressure for stage 3 CKD patients while maintaining potassium excretion benefits.
New data regarding GLP-1 receptor agonists, specifically elecoglipron, indicated a reduction in urine albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes. In geriatric populations, real-world data involving over 10,000 adults aged 80 or older suggested that SGLT2 inhibitor therapy was linked to an 18% reduction in all-cause mortality, though it may increase risks for acute kidney injury and specific cardiac events.
Digital health advancements were also a focus, including the use of large language models (LLMs) to draft prior authorization letters and the implementation of risk-stratification models to improve the uptake of guideline-directed medical therapies. Researchers also discussed the potential for point-of-care testing to bridge diagnostic gaps in Africa, where CKD affects an estimated 13.7% of adults.
Entities
ASN Kidney Week 2026 · American Society of Nephrology · Catholic Kwandong University International St. Mary’s Hospital · Denver, Colorado · FIND-CKD trial · South Korea